Drug for diabetic individuals with comorbidities is introduced by Glenmark Pharma

On Thursday, Glenmark Pharmaceuticals announced the availability of a fixed-dose combination for the management of diabetes in patients with coexisting conditions.

The Mumbai-based pharmaceutical business claimed to be the first to market a fixed-dose combination of teneligliptin (20 mg) and dapagliflozin (5 mg/10 mg) for the treatment of adults with type 2 diabetes.

It is sold under the trade name Zita D and must be taken once daily by prescription to improve glycemic control and prevent complications in adult patients with type 2 diabetes, particularly those who have comorbidities, according to a statement from Glenmark Pharma. It contains the active ingredients teneligliptin (20 mg) and dapagliflozin (5 mg/10 mg).

In India, the prevalence of diabetes is rising alarmingly, and eight out of ten diabetic patients experience comorbid conditions, according to Glenmark Pharmaceuticals EVP & Business Head India Formulations Alok Malik.

He continued, "The new medication is a well-studied, cost-effective fixed-dose combination that will dramatically enhance glycemic control in adult patients."

For FDC of Teneligliptin 20 mg + Dapagliflozin 5 mg, Glenmark said that Zita D costs roughly Rs 14 per tablet, while for FDC of Teneligliptin 20 mg, it costs Rs 15.

10 mg of dapagliflozin every day. The market for oral anti-diabetic medications in India is predicted to reach Rs 11,796 crore for the 12-month period ending in September 2022, up 7% annually from the same time the previous year, according to IQVIA sales statistics.

By 2045, 125 million people in India are anticipated to have diabetes, according to the International Diabetes Federation (IDF). 77% of the individuals among them have uncontrolled diabetes.

Furthermore, according to the medication company, one or more comorbidities are present in nearly eight out of 10 diabetic patients in India.